Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant vebicototamab plus pucotenlimab for locally advanced penile squamous cell carcinoma
ChiCTR2600135851Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebได้cototamab and pucotenlimab in penile squamous cell carcinoma (PSCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: R0 resection rate. Started Jul 2026; status: recruiting.
02
Drugs
vebได้cototamabpucotenlimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2600135851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135851.